Develops and commercializes innovative molecularly targeted and immuno-oncology drugs for cancer treatment.
BeiGene, Ltd. is a pioneering biotechnology company that operates on a global scale, specializing in the discovery, development, manufacturing, and commercialization of innovative medicines. At the forefront of its portfolio are cutting-edge therapies designed to address a wide spectrum of medical needs worldwide. Among its notable products is BRUKINSA, which targets relapsed/refractory mantle cell lymphoma, showcasing the company's commitment to advancing treatments for hematological malignancies.
The company's robust pipeline includes a range of clinical stage drug candidates that hold promise across various therapeutic areas. Zanubrutinib, for instance, is a potent BTK inhibitor intended for treating lymphomas, while Tislelizumab, an anti-PD-1 antibody, is aimed at both solid and hematological cancers. Additionally, BeiGene, Ltd. is advancing Lifirafenib and BGB-3245, which target melanoma, non-small cell lung cancer (NSCLC), and other challenging malignancies, underscoring its dedication to enhancing treatment options through innovative research.
Founded in 2010 and headquartered in Cambridge, Massachusetts, BeiGene, Ltd. has strategically positioned itself through key collaborations with prominent entities such as Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. These partnerships facilitate synergistic efforts in advancing groundbreaking therapies and expanding the frontiers of biopharmaceutical innovation to benefit patients worldwide.